Get the Stockscreener App
1.03
84.03%
0.4703
Pre-market:
1.02
-0.01
-0.97%
Invivyd Inc stock is traded at $1.03, with a volume of 185.71M.
It is up +84.03% in the last 24 hours and up +31.21% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$0.5597
Open:
$0.9452
24h Volume:
185.71M
Relative Volume:
45.03
Market Cap:
$123.56M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.5255
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
+80.39%
1M Performance:
+31.21%
6M Performance:
-16.26%
1Y Performance:
-20.16%
1-Day Range:
$0.81
$1.14
1-Week Range:
$0.483
$1.14
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.03 | 69.71M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Can trapped investors hope for a rebound in Invivyd Inc.July 2025 Intraday Action & Daily Entry Point Alerts - Newser
Is now a turning point for Invivyd Inc.Bond Market & Long-Term Safe Investment Plans - Newser
Invivyd (IVVD.O) Suffers Massive 78% Drop—What’s Behind the Sharp Move? - AInvest
Will Invivyd Inc. stock go up soonJuly 2025 Volume & Consistent Profit Trading Strategies - Newser
Invivyd stock jumps on interest in COVID therapy (IVVD:NASDAQ) - Seeking Alpha
Using RSI to spot recovery in Invivyd IncTrade Performance Summary & Daily Market Momentum Tracking - Newser
Can machine learning forecast Invivyd Inc. recoveryMarket Volume Report & Weekly Chart Analysis and Trade Guides - Newser
Institutional scanner results for Invivyd Inc.Dividend Hike & Growth Oriented Trading Recommendations - Newser
Invivyd Inc. stock daily chart insightsWeekly Trade Recap & Risk Controlled Swing Alerts - Newser
Shares of Invivyd surge on hopes for non-vaccine Covid therapy amid political shift - Investing.com
Invivyd Inc. Stock Surge: Is This the Time to Buy? - timothysykes.com
How to monitor Invivyd Inc. with trend dashboardsJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Invivyd Stock Soars 126.79% on $57.5M Public Offering - AInvest
Understanding Invivyd Inc.’s price movementTrade Volume Summary & Accurate Trade Setup Notifications - Newser
Is Invivyd Inc. still worth holding after the dipJuly 2025 Movers & Breakout Confirmation Trade Signals - Newser
Invivyd Stock Soars 77.68% on $57.5M Public Offering - AInvest
Why Invivyd Inc. is moving todayMarket Risk Summary & Expert Verified Movement Alerts - Newser
What makes Invivyd Inc. stock price move sharplyEntry Point & Daily Technical Forecast Reports - Newser
Heatmap analysis for Invivyd Inc. and competitorsJuly 2025 Patterns & Technical Entry and Exit Alerts - Newser
Statistical indicators supporting Invivyd Inc.’s strengthJuly 2025 Sentiment & Verified Momentum Watchlists - Newser
Technical Models Suggest Invivyd Inc. May Rebound Soon2025 Technical Overview & Weekly Watchlist for Consistent Profits - 클래시안
Invivyd Raises $53.5 Million in Public Offering - MSN
Trend analysis for Invivyd Inc. this week2025 Key Lessons & AI Based Buy/Sell Signal Reports - Newser
Institutional Tools Highlight Unusual Flow in Invivyd Inc.July 2025 Technicals & Low Drawdown Momentum Trade Ideas - 더경남뉴스
Invivyd stock falls after pricing capital raise of $50M via securities offering - MSN
Invivyd Announces Proposed Public Offering of Common Stock for $513M. - AInvest
Invivyd closes $57.5 million public offering to fund clinical programs By Investing.com - Investing.com South Africa
Invivyd Raises $57.5 Million Through Public Offering - AInvest
Invivyd Closes $57.5 Million Public Offering - MarketScreener
Invivyd closes $57.5 million public offering to fund clinical programs - Investing.com
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares - MarketScreener
$57.5 Million Biotech Fundraise: Invivyd Secures Major Backing for COVID and RSV Drug Development - Stock Titan
Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge - simplywall.st
Invivyd Announces $50M Public Offering to Fund Clinical Programs, Analysts Predict Significant Upside with Average Price Target of $4.00 - AInvest
Invivyd Raises $50 Million in Public Offering to Fund Clinical and Research Programs - AInvest
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates - MSN
Order flow analysis tools used on Invivyd Inc.2025 Momentum Check & Fast Moving Stock Trade Plans - Newser
Invivyd Shares Fall After Company Prices $50 Million Offering of Stock, Warrants - MarketScreener
Invivyd Plummets 20%: Capital Raise Sparks Investor Exodus – What’s Next for the Biotech? - AInvest
Invivyd, Inc. shares fall 16.72% premarket after announcing a $50 million public offering. - AInvest
Invivyd Stock Plunges 16.25% Amid Public Offering Concerns - AInvest
Invivyd's Stock Drops as Company Raises $50M Through Securities Offering - AInvest
Invivyd Initiates Public Offering of Common Stock and Grants Underwriters Option for Additional Shares - AInvest
Invivyd Reports Strong Revenue Growth Amid Strategic Advances - TipRanks
Exit strategy if you’re trapped in Invivyd Inc.Gold Moves & Low Drawdown Trading Strategies - Newser
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Invivyd prices $50 million public offering at $0.52 per share - Investing.com
Invivyd IPO: Company Prices Shares at $0.52 Each - AInvest
$50 Million Capital Raise: Invivyd Secures Funding for Long COVID and RSV Research Programs - Stock Titan
Invivyd prices public offering at $0.52 per share - MarketScreener
Invivyd announces proposed public offering of common stock - MSN
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
88,987 |
| Duke William E. | Chief Financial Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Duke William E. | Chief Financial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Green Julie | Chief Human Resources Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 19 '25 |
Sale |
0.57 |
49,402 |
27,991 |
84,446 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '25 |
Sale |
0.65 |
33,352 |
21,685 |
133,848 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 19 '25 |
Sale |
0.57 |
27,420 |
15,536 |
53,068 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '25 |
Sale |
0.65 |
18,512 |
12,037 |
80,488 |
0.95%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):